LIRAGLUTIDE IMPURITY INTELLIGENCE
Liraglutide Impurities
Documented impurity records for liraglutide, classified by type and evidence status. Each record includes scientific rationale and reference material availability.
All impurity records are classified by evidence source. Evidence status reflects the quality of available scientific support, not commercial availability.
IMPURITY RECORDS
Characterized Impurities — 4 Records
Liraglutide Des-Fatty Acid Impurity
Liraglutide Backbone Peptide
Liraglutide peptide backbone without the C16 fatty acid side chain. Loss of the palmitic acid modification via hydrolysis of the glutamic acid spacer linkage is a primary degradation and process-related impurity. This impurity has reduced albumin-binding affinity and altered pharmacokinetic profile.
Liraglutide Met Oxidation Impurity
Oxidation product at methionine residue(s) in the liraglutide sequence. Met oxidation is a well-characterised degradation pathway for GLP-1 analogues under oxidative stress conditions. The oxidised form may be detected by LC-MS as a +16 Da mass shift.
Liraglutide Deamidation Impurity
Deamidation product at asparagine or glutamine residue(s) in the liraglutide sequence. Deamidation introduces a +1 Da mass shift and may affect chromatographic retention. Relevant under acidic or elevated temperature stress conditions.
Liraglutide [Arg³⁴] Sequence Variant
Liraglutide Arg34 Impurity
Sequence variant with arginine at position 34. Liraglutide contains a Lys³⁴→Arg³⁴ substitution relative to native GLP-1(7-37); this impurity arises from incomplete or incorrect amino acid incorporation during synthesis. Reported in the scientific literature as a relevant process-related impurity.